Fast-tracked innovation: orforglipron approval under the FDA’s National Priority Voucher program

To the Editor, The FDA Commissioner’s National Priority Voucher (CNPV) program was announced in June 2025. This program utilizes a collaborative tumor board-style review process to speed up the review and approval of products that match one of the five described crucial U.S. national health priorities: public health crisis response, innovative breakthrough therapies, large unmet medical needs, onshoring and supply chain resilience, and affordability. This pilot program is being used as a means to reduce the review timing for drugs and other biological product applications. This decision represents a hallmark in regulatory history. It marks the first new molecular entity (NME) approved through this program, becoming the fastest approval of an NME since 2002. The CNPV program markedly shortens the review timeline to 1–2 months[1]. This duration is significantly shorter than other review pathways, such as the priority review pathway, which requires 6 months to take action on an application and 10 months under standard review[2]. The vouchers for the CNPV program may be granted by the FDA itself for the review of a company’s particular drug product application. The U.S. Food and Drug Administration approved Foundayo (orforglipron) on April 1, 2026. It is issued to be used in combination with increased physical activity and a reduced-calorie diet to lessen excess body weight and maintain the effects of weight reduction for a long time in adults with obesity, or overweight adults with at least one obesity-related comorbidity[3]. The approval of the drug is noteworthy as it delivers a first-in-class oral GLP-1 therapy, representing an essential unmet need in obesity, while also reflecting a paradigm shift toward fast-paced, regulatory approval under the FDA’s CNPV program. Orforglipron is a newly developed, active non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. It is taken orally once daily and has a prolonged half-life of about 24–29 hours, making it a potent partial agonist of GLP-1 receptors[4]. It selectively binds to and activates the GLP-1 receptor, a G protein–coupled receptor, which increases intracellular cAMP levels, thereby enhancing glucose-dependent insulin secretion with little effect on β-arrestin recruitment. This is important as β-arrestin is involved in receptor internalization and desensitization; by limiting this pathway, orforglipron prolongs receptor activity and enhances efficacy. Thus, orforglipron is used in the treatment of type 2 diabetes and chronic weight management, improving glycemic control, reducing body weight, and providing cardiovascular benefits[5]. The approval of orforglipron under the FDA’s National Priority Voucher program highlights its clinical and regulatory significance. From a clinical perspective, it fills the need for an effective oral GLP-1 treatment, having similar effects as injections but being more convenient to administer, which improves treatment adherence and helps patients follow the treatment better. Two randomized, double-blind, placebo-controlled trials showed that 72 weeks of treatment, combined with reduced calorie intake and increased physical activity, led to significant reductions in HbA1c levels and body weight in obese adults or adults who are overweight with comorbidities. Clinically, this approval will encourage pharmaceutical companies to develop more non-peptide oral drugs like this. It may also influence regulatory systems worldwide by supporting faster approval for new medicines[3]. The labeling of Foundayo includes a boxed warning for thyroid C-cell tumors. It should not be used in patients with a genetic history of medullary thyroid cancer or in patients with multiple endocrine neoplasia (MEN) syndrome type 2. The most common adverse effects of Foundayo are related to the gastrointestinal system, which include nausea, emesis, constipation, diarrhea, stomach pain, dyspepsia, burping, bloating, and gastroesophageal reflux disease (GERD). Adverse effects related to other systems include headaches, fatigue, and hair loss. There are some safety concerns regarding the development of pancreatitis, severe gastrointestinal side effects, acute kidney injury secondary to low blood volume, low blood glucose levels, diabetic retinopathy in type 2 diabetic patients, hypersensitivity reactions, acute biliary disease, and aspiration into the lungs during deep anesthesia. The labeling of Foundayo includes a boxed warning for thyroid C-cell tumors, and it is not recommended for individuals with a personal or family history of medullary thyroid carcinoma or MEN syndrome type 2[3]. Higher doses are associated with a higher risk of treatment discontinuation[6]. Orforglipron has positive therapeutic effects on weight loss, HbA1c levels, and lipid profiles. Although gastrointestinal adverse effects and discontinuation incidences occur, severe adverse event and death rates are similar to the placebo group, supporting acceptable tolerability and safety[6]. There are a limited number of clinical trials, which are of short duration, providing limited evidence for long-term safety and sustained therapeutic effects. Moreover, all the trials are funded by the pharmaceutical manufacturer, so there is a higher risk of funding bias[6]. In conclusion, the approval of orforglipron represents the importance of modern drug development. It also highlights the potential of such programs to improve drug approval systems and facilitate easy patient access to important therapies. In addition, orforglipron shows significant improvements in glycemic and lipid profiles for managing diabetes and obesity[6]. Its long half-life supports once-daily oral administration without water or food restrictions, suggesting its use over injectable GLP-1 receptor agonists[5]. Although it may cause slightly less weight loss compared to drugs such as tirzepatide and retatrutide, its oral form and similar safety profile make it more convenient and useful clinically[4]. Overall, orforglipron highlights the future potential of non-peptide therapies; however, a balanced and cautious approach is needed to ensure its long-term safety, affordability, and fair access for patients.